Dr Steven Smith BSc PhD
- Steven Smith's Contacts
- Room 237
- Keppel Street
- WC1E 7HT
- T: 020 7927 2295
- F: 020 7637 4314
Steven Smith is an immunologist with a background in cellular immunity, in particular the protective and disease-related roles of T-cells. Having obtained a B.Sc. in Medical Sciences from the University of Leeds, Steven carried out (and received his Ph.D. for) a project at the Imperial Cancer Research Fund (now Cancer Research UK) Cancer Medicine Research Unit at St. James's University Hospital, Leeds, investigating the CD8 T-cell stimulating properties of a DNA vaccine encoding multiple, melanoma-associated epitopes. Following a post-doctoral position at the Edward Jenner Institute for Vaccine Research in which he examined the role of auto-reactive CD8 T-cells and T-cell regulation in the context of joint inflammation, Steven joined the group of Prof. Hazel Dockrell where he has been concerned with the cellular immune response to BCG vaccination and more generally with immune mechanisms that might provide protection against tuberculosis infection and disease.
Steven's main teaching roles at LSHTM are as lecturer, practical class organiser and personal tutor for the London-based MSc in Immunology of Infectious Diseases. He is also the deputy module organiser for the Immunology of Infection and Vaccines module of the distance learning programme. Steven has delivered lectures at the Uganda Virus Research Institute (Entebbe, Uganda) on the TB section of the Makerere/UVRI Infection and Immunity ResearchTrainingProgramme short course, “Immunology in the Tropics”.
Steven is currently part of Prof Hazel Dockrell's team, looking at immune responses to BCG vaccination. His work is funded by the European Union as part of two large consortium projects. The "Correlates of Protection" work package of the TBVAC2020 project involves the use of a variety of state-of-the-art immunological investigations (multi-parameter flow cytometry, multiplex bead array assays and mycobacterial growth inhibition assay) to investigate the infant immune response to BCG vaccination. Although BCG is known to protect infants from childhood forms of tuberculosis, the mechanisms of immunity are unclear. Characteristics of the immune response, as measured by these techniques, may act as a biomarkers of protection against TB. Identifying such biomarkers, as well as aiding our understanding of BCG, will also facilitate the development of improved vaccines for tuberculosis.
EURIPRED is also a multi-centre EU consortium project aimed at improving access of vaccine developers to knowledge and expertise within the European vaccine community. Steven's work at LSHTM is focussed on developing and harmonising with other groups, the best, most consistent and transferable assays for the measurement of novel vaccine induced immune responses in trial settings worldwide.
Steven maintains an ongoing research interest in the environmental (including infection-related, vaccine-related and nutritional) factors that influence both innate and acquired immune responses to BCG vaccination and tuberculosis infection.
- Innate immunity
- T-cell immunology
Disease and Health Conditions
- Infectious disease
- European Union
- Sub-Saharan Africa (all income levels)
- United Kingdom
- BCG Vaccination
- CD8 T Cells
- Cellular Immunology
- Flow Cytometry
- Infectious Diseases
- Multiplex Assays
- TB Centre
The Use of Interferon Gamma Inducible Protein 10 as a Potential Biomarker in the Diagnosis of Latent Tuberculosis Infection in Uganda.
Biraro, I.A. ; Kimuda, S. ; Egesa, M. ; Cose, S. ; Webb, E.L. ; Joloba, M. ; Smith, S.G. ; Elliott, A.M. ; Dockrell, H.M. ; Katamba, A. ;
PLoS One, 2016; 11(1):e0146098
Polyfunctional CD4 T-cells correlate with in vitro mycobacterial growth inhibition following Mycobacterium bovis BCG-vaccination of infants.
Smith, S.G. ; Zelmer, A. ; Blitz, R. ; Fletcher, H.A. ; Dockrell, H.M. ;
The impact of maternal infection with Mycobacterium tuberculosis on the infant response to bacille Calmette-Guérin immunization.
Mawa, P.A. ; Nkurunungi, G. ; Egesa, M. ; Webb, E.L. ; Smith, S.G. ; Kizindo, R. ; Akello, M. ; Lule, S.A. ; Muwanga, M. ; Dockrell, H.M. ; Cose, S. ; Elliott, A.M. ;
Philos Trans R Soc Lond B Biol Sci, 2015; 370(1671)
Intracellular Cytokine Staining and Flow Cytometry: Considerations for Application in Clinical Trials of Novel Tuberculosis Vaccines.
Smith, S.G. ; Smits, K. ; Joosten, S.A. ; van Meijgaarden, K.E. ; Satti, I. ; Fletcher, H.A. ; Caccamo, N. ; Dieli, F. ; Mascart, F. ; McShane, H. ; Dockrell, H.M. ; Ottenhoff, T.H. ; TBVI TB Biomarker Working Group, . ;
PLoS One, 2015; 10(9):e0138042
Effect of isoniazid preventive therapy on immune responses to mycobacterium tuberculosis: an open label randomised, controlled, exploratory study.
Biraro, I.A. ; Egesa, M. ; Kimuda, S. ; Smith, S.G. ; Toulza, F. ; Levin, J. ; Joloba, M. ; Katamba, A. ; Cose, S. ; Dockrell, H.M. ; Elliott, A.M. ;
BMC Infect Dis, 2015; 15(1):438
Factors affecting immunogenicity of BCG in infants, a study in Malawi, The Gambia and the UK.
Hur, Y.G. ; Gorak-Stolinska, P. ; Lalor, M.K. ; Mvula, H. ; Floyd, S. ; Raynes, J. ; Ben-Smith, A. ; Fitchett, J.R. ; Flanagan, K.L. ; Burl, S. ; Ota, M.O. ; Crampin, A.C. ; Smith, S.G. ; Dockrell, H.M. ;
BMC Infect Dis, 2014; 14(1):184
Broad heparin-binding haemagglutinin-specific cytokine and chemokine response in infants following Mycobacterium bovis BCG vaccination.
Smith, S.G.; Lecher, S.; Blitz, R.; Locht, C.; Dockrell, H.M.;
Eur J Immunol, 2012; 42(9):2511-22
Mycobacterium tuberculosis PPD-induced immune biomarkers measurable in vitro following BCG vaccination of UK adolescents by multiplex bead array and intracellular cytokine staining.
Smith, S.G.; Lalor, M.K.; Gorak-Stolinska, P.; Blitz, R.; Beveridge, N.E.; Worth, A.; McShane, H.; Dockrell, H.M.;
BMC Immunol, 2010; 11(1):35
- → View all Dr Steven Smith 's publications